ATE501156T1 - Cyclopropyl-annelierte indolobenzazepine als hcv- ns5b-inhibitoren - Google Patents

Cyclopropyl-annelierte indolobenzazepine als hcv- ns5b-inhibitoren

Info

Publication number
ATE501156T1
ATE501156T1 AT07761873T AT07761873T ATE501156T1 AT E501156 T1 ATE501156 T1 AT E501156T1 AT 07761873 T AT07761873 T AT 07761873T AT 07761873 T AT07761873 T AT 07761873T AT E501156 T1 ATE501156 T1 AT E501156T1
Authority
AT
Austria
Prior art keywords
indolobenzazepines
annelated
cyclopropyl
hcv ns5b
ns5b inhibitors
Prior art date
Application number
AT07761873T
Other languages
English (en)
Inventor
John A Bender
Min Ding
Robert G Gentles
Piyasena Hewawasam
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38512732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE501156(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE501156T1 publication Critical patent/ATE501156T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
AT07761873T 2006-05-17 2007-05-04 Cyclopropyl-annelierte indolobenzazepine als hcv- ns5b-inhibitoren ATE501156T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US80112506P 2006-05-17 2006-05-17
US80200506P 2006-05-19 2006-05-19
US85208406P 2006-10-16 2006-10-16
US89475707P 2007-03-14 2007-03-14
PCT/US2007/068209 WO2007136982A1 (en) 2006-05-17 2007-05-04 Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors

Publications (1)

Publication Number Publication Date
ATE501156T1 true ATE501156T1 (de) 2011-03-15

Family

ID=38512732

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07761873T ATE501156T1 (de) 2006-05-17 2007-05-04 Cyclopropyl-annelierte indolobenzazepine als hcv- ns5b-inhibitoren

Country Status (24)

Country Link
US (1) US7456166B2 (de)
EP (1) EP2024375B1 (de)
JP (1) JP5284952B2 (de)
KR (1) KR101417145B1 (de)
AR (1) AR061008A1 (de)
AT (1) ATE501156T1 (de)
AU (1) AU2007253998B2 (de)
BR (1) BRPI0711821A2 (de)
CA (1) CA2651690C (de)
CY (1) CY1111526T1 (de)
DE (1) DE602007013036D1 (de)
DK (1) DK2024375T3 (de)
EA (1) EA015286B1 (de)
HR (1) HRP20110194T1 (de)
IL (1) IL195025A (de)
MX (1) MX2008014435A (de)
NO (1) NO341663B1 (de)
NZ (1) NZ572555A (de)
PE (1) PE20080070A1 (de)
PL (1) PL2024375T3 (de)
SI (1) SI2024375T1 (de)
TW (1) TWI401244B (de)
WO (1) WO2007136982A1 (de)
ZA (1) ZA200809548B (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049622A1 (ja) * 2003-11-19 2005-06-02 Japan Tobacco Inc. ５－５員縮合複素環化合物及びそのｈｃｖポリメラーゼ阻害剤としての用途
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US7521443B2 (en) * 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
DE602007006796D1 (de) * 2006-05-25 2010-07-08 Bristol Myers Squibb Co Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b-hemmer
US7541351B2 (en) * 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7541352B2 (en) * 2007-02-02 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7517872B2 (en) * 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7998951B2 (en) * 2007-03-05 2011-08-16 Bristol-Myers Squibb Company HCV NS5B inhibitors
CN101679437B (zh) 2007-03-13 2013-04-17 百时美施贵宝公司 环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂
US7538102B2 (en) * 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7541353B2 (en) * 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7547690B2 (en) * 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7521444B2 (en) * 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538103B2 (en) * 2007-03-15 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP2494991A1 (de) 2007-05-04 2012-09-05 Vertex Pharmaceuticals Incorporated Kombinationstherapie zur Behandlung von HIV-Infektionen
US7642251B2 (en) * 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7652004B2 (en) * 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8143243B2 (en) * 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
CN101918410B (zh) * 2007-11-20 2013-02-27 百时美施贵宝公司 与环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂
US8124601B2 (en) 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
CN103483251A (zh) 2007-12-19 2014-01-01 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
AU2008339917B2 (en) 2007-12-24 2013-02-07 Tibotec Pharmaceuticals Macrocyclic indoles as hepatitis C virus inhibitors
CN102046630A (zh) * 2008-03-27 2011-05-04 百时美施贵宝公司 吡咯烷稠合的吲哚并苯并二氮杂*hcv ns5b抑制剂
JP2011515496A (ja) * 2008-03-27 2011-05-19 ブリストル−マイヤーズ スクイブ カンパニー ジオキソランおよびジオキソラノン縮合インドロベンザジアゼピンｈｃｖｎｓ５ｂ阻害剤
JP2011515486A (ja) * 2008-03-27 2011-05-19 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎の治療用化合物
US8133884B2 (en) * 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
TWI454476B (zh) * 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
AU2010203656A1 (en) 2009-01-07 2011-07-21 Scynexis, Inc. Cyclosporine derivative for use in the treatment of HCV and HIV infection
US8143244B2 (en) * 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
CN103097356B (zh) 2010-06-24 2016-01-13 爱尔兰詹森科学公司 13-环己基-3-甲氧基-6-[甲基-(2-{2-[甲基-(氨磺酰基)-氨基]-乙氧基}-乙基)-氨基甲酰基]-7H-吲哚并-[2,1-a]-[2]-苯并氮杂*-10-羧酸的制备
US20120196794A1 (en) * 2010-08-06 2012-08-02 Bristol-Myers Squibb Company Combinations of Hepatitis C Virus Inhibitors
CN103649079B (zh) 2010-12-22 2016-11-16 Abbvie公司 丙型肝炎抑制剂及其用途
US8951964B2 (en) 2010-12-30 2015-02-10 Abbvie Inc. Phenanthridine macrocyclic hepatitis C serine protease inhibitors
CA2822556A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8716275B2 (en) * 2011-10-20 2014-05-06 Bristol-Myers Squibb Company Compound for the treatment of hepatitis C
US9556204B2 (en) 2012-07-18 2017-01-31 Bristol-Myers Squibb Company Methods and intermediates for the preparation of (4bS,5aR)-12-cyclohexyl-N-(N,N-dimethylsulfamoyl)-3-methoxy-5a-((1R,5S)-3-methyl-3,8-diazabicyclo [3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-A]indole-9-carboxamide
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US752354A (en) * 1904-02-16 Composition post
US753137A (en) * 1904-02-23 Dust-pan
US756203A (en) * 1903-11-14 1904-04-05 Oliver E Barthel Muffler.
ATE428714T1 (de) 2004-02-24 2009-05-15 Japan Tobacco Inc Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor
US7348425B2 (en) 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
DE502005002697D1 (de) 2004-10-13 2008-03-13 Merck Patent Gmbh Als kinaseinhibitoren geeignete derivate des n,n'-diphenylharnstoffs
EP1807397A2 (de) * 2004-10-26 2007-07-18 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Tetrazyklische indolderivate als antivirale wirkstoffe
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) * 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) * 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents

Also Published As

Publication number Publication date
JP2009537557A (ja) 2009-10-29
DE602007013036D1 (de) 2011-04-21
EP2024375A1 (de) 2009-02-18
IL195025A0 (en) 2009-08-03
EA200802346A1 (ru) 2009-06-30
WO2007136982A1 (en) 2007-11-29
KR101417145B1 (ko) 2014-07-08
ZA200809548B (en) 2009-12-30
EA015286B1 (ru) 2011-06-30
HRP20110194T1 (hr) 2011-04-30
TWI401244B (zh) 2013-07-11
CA2651690A1 (en) 2007-11-29
US20070270405A1 (en) 2007-11-22
NZ572555A (en) 2010-11-26
PL2024375T3 (pl) 2011-07-29
EP2024375B1 (de) 2011-03-09
TW200804282A (en) 2008-01-16
NO341663B1 (no) 2017-12-18
AU2007253998B2 (en) 2012-03-15
MX2008014435A (es) 2008-11-27
SI2024375T1 (sl) 2011-10-28
DK2024375T3 (da) 2011-06-27
KR20090008344A (ko) 2009-01-21
CY1111526T1 (el) 2016-02-10
PE20080070A1 (es) 2008-03-10
AR061008A1 (es) 2008-07-30
US7456166B2 (en) 2008-11-25
NO20084637L (no) 2008-12-15
BRPI0711821A2 (pt) 2012-01-17
JP5284952B2 (ja) 2013-09-11
HK1122814A1 (en) 2009-05-29
CA2651690C (en) 2014-11-04
IL195025A (en) 2013-09-30
AU2007253998A1 (en) 2007-11-29

Similar Documents

Publication Publication Date Title
ATE501156T1 (de) Cyclopropyl-annelierte indolobenzazepine als hcv- ns5b-inhibitoren
DK2373172T3 (da) Hcv-ns5a-hæmmere
EP2076278A4 (de) Hcv-ns3 -proteasehemmer
EP2271345A4 (de) Hcv-ns3 -proteasehemmer
BRPI0923184A2 (pt) inibidores de hcv ns3 protease
DK2084175T3 (da) HCV nucleosidinhibitor
BRPI0807087A2 (pt) Inibidores de hcv macrocíclicos substituídos de pirimidina
DK1924593T3 (da) HCV NS3-proteaseinhibitorer
EP2083844A4 (de) Inhibitoren der hcv-ns3-protease
EP2079480A4 (de) Hcv-ns3 -proteasehemmer
CY2017005I1 (el) Μακροκυκλικες ενωσεις κινοξαλινης ως αναστολεις πρωτεασεις ns3 του hcv
BRPI0807887A2 (pt) Compostos macrocíclicos como inibidores de hcv ns3 protease.
IL198401A0 (en) Hcv ns3 protease inhibitors
CY2015004I2 (el) Αναστολεις του ιου της ηπατιτιδας c
ATE543816T1 (de) Azacycloalkanderivate als inhibitoren von stearoyl-coenzym-a-delta-9-desaturase
ATE400271T1 (de) Aryl-pyridinderivate als 11-beta-hsd1-hemmer
ATE510825T1 (de) Acylaminopyrazole als fgfr-inhibitoren
IL213279A0 (en) Inhibitors of hcv ns5a
DE602007008837D1 (de) Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
ATE420076T1 (de) Indozolonderivate als 11b-hsd1-inhibitoren
ATE467623T1 (de) Diazepan-acetamidderivate als selektive 11-hsd1- hemmer
ATE549333T1 (de) Neue sulfonylpyrrole als hdac-inhibitoren
ATE452132T1 (de) Benzimidazolthiophenverbindungen als plk- inhibitoren
ATE495153T1 (de) Arylsulfonylpyrrolidine als 5-ht6-inhibitoren
ATE462692T1 (de) 3-amino-1-arylpropyl-indole als monoamin- wiederaufnahmehemmer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2024375

Country of ref document: EP